Drug intelligence / Profile preview

doxorubicin + cyclophosphamide followed by docetaxel

Development stage: Unknown
Lead developer: Farmitalia
Modality: Small Molecules
Administration: Intravenous

Overview

This combination involves the sequential administration of doxorubicin and cyclophosphamide (AC) followed by docetaxel. **Doxorubicin** is an anthracycline antibiotic that intercalates DNA strands, inhibiting the synthesis of macromolecules and inducing apoptosis in cancer cells. **Cyclophosphamide** is an alkylating agent that forms DNA cross-links, leading to cell death. **Docetaxel** is a taxane that stabilizes microtubules, preventing cell division. This regimen is used primarily in the treatment of breast cancer.

Other names: AC followed by docetaxelAC-T

Targets

DNATOP2A (DNA topoisomerase II)

Beyond the preview

Go deeper on doxorubicin + cyclophosphamide followed by docetaxel.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on doxorubicin + cyclophosphamide followed by docetaxel.

Explore the full profile